Please login to the form below

Not currently logged in

kinase inhibitor

This page shows the latest kinase inhibitor news and features for those working in and with pharma, biotech and healthcare.

Amgen snaps up Celgene’s Otezla for $13.4bn

Amgen snaps up Celgene’s Otezla for $13.4bn

Celgene needed to sell off Otezla after the US anti-trust authority the FTC concluded in June that having the oral medicine in the same portfolio as BMS’ pipeline tyrosine kinase ... 2 (TYK2) inhibitor would give too big a share of the market.

Latest news

More from news
Approximately 0 fully matching, plus 153 partially matching documents found.

Latest Intelligence

  • Deal Watch January 2018

    The headline value contains significant sales milestones linked to performance of Impact's lead phase III stage asset fedratinib, an oral JAK2 kinase inhibitor in development for the treatment of myelofibrosis ... Acquisition company -  remaining 90%. 9

  • Deal Watch September 2016 Deal Watch September 2016

    No financial terms were disclosed. Genentech signed an exclusive licence [global excluding South Korea] with Hanmi Pharmaceutical to develop and market HM95573, a pan-RAF inhibitor. ... 1, 000+. Hanmi / Genentech. Licence. HM95573, a selective

  • Deal Watch June 2016 Deal Watch June 2016

    acquisition assets. 350. CrystalGenomics/ Aptose Biosciences. CG026806 inhibitor of Bruton's tyrosine kinase, FMS-like tyrosine kinase 3 and Aurora kinases (preclinical). † ... acquisition company. 105. Nektar Therapeutics/ Daiichi Sankyo Europe.

  • Deal Watch May 2016 Deal Watch May 2016

    Paying a 55% premium at $99.25 per share, the acquisition brings crisaborole, a topical PDE4 inhibitor for mild to moderate atopic dermatitis (eczema) with estimated peak sales of $2bn. ... 282. Carna Biosciences/ ProNAi Therapeutics. Licence. $0.9m

  • Pharma deals in September 2015 Pharma deals in September 2015

    Purdue licensed VM Pharma's allosteric selective tropomyosin receptor kinase A (TrkA) inhibitor programme for chronic pain. ... Collaboration - public private partnership. 220. VM Pharma. Purdue Pharma. VM902A a signalling protein tropomyosin receptor

More from intelligence
Approximately 0 fully matching, plus 18 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 2 partially matching documents found.

Featured jobs

Subscribe to our email news alerts


Add my company
mXm Medical Communications

mXm Medical Communications meets the needs of pharmaceutical marketers and medics who require a highly experienced, bespoke service from their...

Latest intelligence

Pharma index map
The 2019 CPhI Pharma Index Report
Examining this year’s industry performance...
Five key trends in precision and personalised healthcare
Here, we deep dive into five of the key trends in precision medicine and personalised healthcare to explore how the healthcare industry is changing and how pharmaceutical and biotech companies...
OPEN Health Graduate Programme: from OPEN VIE to OPEN Health Medical Communications
Isobel Owens shares her experience of the OPEN Health Graduate Programme from OPEN VIE to OPEN Health Medical Communications...